MCM6 [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== MCM6 ======
[[Minichromosome maintenance protein]]s (MCMs) play an essential role in [[DNA replication]] and other cellular activities. 

The long term risk of tumor [[recurrence]] is higher in adamantine epithelioma (AE) than squamous papillary tumor (SP) and it is associated with MCM6 and [[DNA topoisomerase II alpha]] expression
((Xu J, Zhang S, You C, Huang S, Cai B, Wang X. Expression of human MCM6 and DNA
Topo II alpha in craniopharyngiomas and its correlation with recurrence of the
tumor. J Neurooncol. 2007 Jun;83(2):183-9. Epub 2007 Apr 5. PubMed PMID:
17410335.
)).

MCM6 [[protein]] expression in [[craniopharyngioma]]s are related to the prognosis of tumor and thus may be useful in predicting the risk of tumor relapse
((Xu JG, You C, Wang XJ, Shuai KG, Wang XS. [Expression of minichromosome
maintenance protein 6 in craniopharyngioma and its correlation with prognosis].
Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jan;38(1):64-7. Chinese. PubMed PMID:
17294730.
)).

In a study, Cai et al., analyzed the relationship between MCM [[mRNA]] expression and clinical parameters in 325 gliomas, and found that MCM6 presented high expression and was associated with poor survival. [[Immunohistochemistry]] analysis of an independent dataset of 423 [[glioma]] tissues confirmed the overexpression of MCM6 protein, especially in [[glioblastoma]]s (GBMs) with shorter [[overall survival]] (OS). Importantly, a combination of MCM6 overexpression with [[IDH1]] mutation further improved the prediction of the prognosis of GBMs. Patients with IDH1 mutation and low MCM6 expression exhibited the longest survival, whereas those with high MCM6 expression and wild-type IDH1 showed the shortest. Collectively, the observation indicates that MCM6 is a [[biomarker]] for predicting poor [[prognosis]] of the patients with glioma
((Cai HQ, Cheng ZJ, Zhang HP, Wang PF, Zhang Y, Hao JJ, Wang MR, Wan JH.
Overexpression of MCM6 predicts poor survival in patients with glioma. Hum
Pathol. 2018 May 9. pii: S0046-8177(18)30154-0. doi:
10.1016/j.humpath.2018.04.024. [Epub ahead of print] PubMed PMID: 29753008.
)).